28549178|t|RhoA / Rock Inhibition Improves the Beneficial Effects of Glucocorticoid Treatment in Dystrophic Muscle: Implications for Stem Cell Depletion
28549178|a|Glucocorticoid treatment represents a standard palliative treatment for Duchenne muscular dystrophy (DMD) patients, but various adverse effects have limited this treatment. In an effort to understand the mechanism(s) by which glucocorticoids impart their effects on the dystrophic muscle, and potentially reduce the adverse effects, we have studied the effect of prednisolone treatment in dystrophin / utrophin double knockout (dKO) mice, which exhibit a severe dystrophic phenotype due to rapid muscle stem cell depletion. Our results indicate that muscle stem cell depletion in dKO muscle is related to upregulation of mTOR, and that prednisolone treatment reduces the expression of mTOR and other pro-inflammatory mediators, consequently slowing down muscle stem cell depletion. However, prednisolone treatment was unable to improve the myogenesis of stem cells and reduce fibrosis in dKO muscle. We then studied whether glucocorticoid treatment can be improved by co-administration of an inhibitor of RhoA / ROCK signaling, which can be activated by glucocorticoids and was found in our previous work to be over-activated in dystrophic muscle. Our results indicate that the combination of RhoA / ROCK inhibition and glucocorticoid treatment in dystrophic muscle have a synergistic effect in alleviating the dystrophic phenotype. Taken together, our study not only shed light on the mechanism by which glucocorticoid imparts its beneficial effect on dystrophic muscle, but also revealed the synergistic effect of RhoA / ROCK inhibition and glucocorticoid treatment, which could lead to the development of more efficient therapeutic approaches for treating DMD patients.
28549178	0	4	RhoA	T116,T126	C0643681
28549178	7	11	Rock	T116,T126	C0389995
28549178	12	22	Inhibition	T044	C2247986
28549178	36	46	Beneficial	T081	C0814225
28549178	47	54	Effects	T080	C1280500
28549178	58	82	Glucocorticoid Treatment	T061	C2922114
28549178	86	103	Dystrophic Muscle	T047	C0026850
28549178	122	131	Stem Cell	T025	C0038250
28549178	132	141	Depletion	T169	C0333668
28549178	142	166	Glucocorticoid treatment	T061	C2922114
28549178	189	209	palliative treatment	T091	C0030231
28549178	214	241	Duchenne muscular dystrophy	T047	C0013264
28549178	243	246	DMD	T047	C0013264
28549178	248	256	patients	T101	C0030705
28549178	270	285	adverse effects	T046	C0879626
28549178	304	313	treatment	T061	C0087111
28549178	346	358	mechanism(s)	T169	C0441712
28549178	368	383	glucocorticoids	T109,T125	C0017710
28549178	397	404	effects	T080	C1280500
28549178	412	429	dystrophic muscle	T047	C0026850
28549178	458	473	adverse effects	T046	C0879626
28549178	495	501	effect	T080	C1280500
28549178	505	517	prednisolone	T109,T121	C0032950
28549178	518	527	treatment	T061	C0087111
28549178	531	541	dystrophin	T028	C1414083
28549178	544	552	utrophin	T028	C1421412
28549178	553	579	double knockout (dKO) mice	T015	C0206745
28549178	604	614	dystrophic	T047	C0026850
28549178	615	624	phenotype	T032	C0031437
28549178	638	654	muscle stem cell	T025	C0599856
28549178	655	664	depletion	T169	C0333668
28549178	692	708	muscle stem cell	T025	C0599856
28549178	709	718	depletion	T169	C0333668
28549178	722	725	dKO	T050	C1522225
28549178	726	732	muscle	T024	C0026845
28549178	747	759	upregulation	T044	C0041904
28549178	763	767	mTOR	T116,T126	C1447315
28549178	778	790	prednisolone	T109,T121	C0032950
28549178	791	800	treatment	T061	C1533734
28549178	813	823	expression	T045	C1171362
28549178	827	831	mTOR	T116,T126	C1447315
28549178	842	868	pro-inflammatory mediators	T123	C0574031
28549178	883	895	slowing down	T080	C0439834
28549178	896	912	muscle stem cell	T025	C0599856
28549178	913	922	depletion	T169	C0333668
28549178	933	945	prednisolone	T109,T121	C0032950
28549178	946	955	treatment	T061	C0087111
28549178	982	992	myogenesis	T042	C0596997
28549178	996	1006	stem cells	T025	C0038250
28549178	1018	1026	fibrosis	T046	C0016059
28549178	1030	1033	dKO	T050	C1522225
28549178	1034	1040	muscle	T024	C0026845
28549178	1066	1090	glucocorticoid treatment	T061	C2922114
28549178	1110	1127	co-administration	T061	C1533734
28549178	1134	1143	inhibitor	T121	C1519313
28549178	1147	1151	RhoA	T116,T126	C0643681
28549178	1154	1158	ROCK	T116,T126	C0389995
28549178	1159	1168	signaling	T044	C0037080
28549178	1196	1211	glucocorticoids	T109,T125	C0017710
28549178	1271	1288	dystrophic muscle	T047	C0026850
28549178	1335	1339	RhoA	T116,T126	C0643681
28549178	1342	1346	ROCK	T116,T126	C0389995
28549178	1347	1357	inhibition	T044	C2247986
28549178	1362	1386	glucocorticoid treatment	T061	C2922114
28549178	1390	1407	dystrophic muscle	T047	C0026850
28549178	1415	1426	synergistic	T080	C2986495
28549178	1427	1433	effect	T080	C1280500
28549178	1453	1463	dystrophic	T047	C0026850
28549178	1464	1473	phenotype	T032	C0031437
28549178	1528	1537	mechanism	T169	C0441712
28549178	1547	1561	glucocorticoid	T109,T125	C0017710
28549178	1574	1584	beneficial	T081	C0814225
28549178	1585	1591	effect	T080	C1280500
28549178	1595	1612	dystrophic muscle	T047	C0026850
28549178	1636	1647	synergistic	T080	C2986495
28549178	1648	1654	effect	T080	C1280500
28549178	1658	1662	RhoA	T116,T126	C0643681
28549178	1665	1669	ROCK	T116,T126	C0389995
28549178	1670	1680	inhibition	T044	C2247986
28549178	1685	1709	glucocorticoid treatment	T061	C2922114
28549178	1765	1787	therapeutic approaches	T061	C0087111
28549178	1792	1800	treating	T169	C1522326
28549178	1801	1804	DMD	T047	C0013264
28549178	1805	1813	patients	T101	C0030705